Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 18/20 | 0.51 |
| ▸ | CTSL | P07711 | 4/20 | 0.46 |
| ▸ | CTSB | P07858 | 3/20 | 0.46 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL696385 | 0.99 | CTSS (0.50) | CTSSCTSLCTSBELOVL6 | |
| SCHEMBL2105994 | 0.88 | CTSS (0.48) | CTSSCTSLCTSBELOVL6 | |
| Hydrochloric Acid SCHEMBL2106530 | 0.87 | CTSS (0.47) | CTSSCTSLCTSBELOVL6 | |
| Hydrochloric Acid SCHEMBL697085 | 0.84 | CTSS (0.56) | CTSSCTSLCTSB | |
| SCHEMBL15327619 | 0.83 | CTSS (0.42) | CTSSCTSLCTSBELOVL6 | |
| SCHEMBL697725 | 0.80 | CTSS (0.74) | CTSSCTSLCTSB | |
| Hydrochloric Acid SCHEMBL694102 | 0.79 | CTSS (0.72) | CTSSCTSLCTSB | |
| SCHEMBL694969 | 0.79 | CTSS (0.43) | CTSSCTSLCTSBELOVL6 | |
| SCHEMBL15327131 | 0.79 | CTSS (0.43) | CTSSCTSLCTSBELOVL6 | |
| SCHEMBL15327130 | 0.79 | CTSS (0.43) | CTSSCTSLCTSBELOVL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | claimed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2421826-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | CTSS 1542/4885CTSL 178/4885CTSB 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.